JP2007532566A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007532566A5 JP2007532566A5 JP2007507499A JP2007507499A JP2007532566A5 JP 2007532566 A5 JP2007532566 A5 JP 2007532566A5 JP 2007507499 A JP2007507499 A JP 2007507499A JP 2007507499 A JP2007507499 A JP 2007507499A JP 2007532566 A5 JP2007532566 A5 JP 2007532566A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- medicament
- antibody
- pain
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56107604P | 2004-04-08 | 2004-04-08 | |
| US60/561,076 | 2004-04-08 | ||
| PCT/US2005/011781 WO2005099756A2 (en) | 2004-04-08 | 2005-04-07 | ErbB ANTAGONISTS FOR PAIN THERAPY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007532566A JP2007532566A (ja) | 2007-11-15 |
| JP2007532566A5 true JP2007532566A5 (https=) | 2008-05-22 |
| JP4969440B2 JP4969440B2 (ja) | 2012-07-04 |
Family
ID=35150505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007507499A Expired - Lifetime JP4969440B2 (ja) | 2004-04-08 | 2005-04-07 | 疼痛治療のためのＥｒｂＢアンタゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20060034840A1 (https=) |
| EP (1) | EP1737489B1 (https=) |
| JP (1) | JP4969440B2 (https=) |
| AT (1) | ATE540696T1 (https=) |
| AU (1) | AU2005232657B2 (https=) |
| CA (1) | CA2563341C (https=) |
| WO (1) | WO2005099756A2 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| WO2004085648A2 (en) | 2003-03-19 | 2004-10-07 | Biogen Idec Ma Inc. | Nogo receptor binding protein |
| SV2006002143A (es) * | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| PT1776136E (pt) | 2004-06-24 | 2012-12-05 | Biogen Idec Inc | Tratamento de estados que envolvem desmielinização |
| KR20140032004A (ko) | 2004-07-22 | 2014-03-13 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP2008523073A (ja) * | 2004-12-07 | 2008-07-03 | ジェネンテック・インコーポレーテッド | Ｈｅｒ阻害剤を用いた治療のための患者の選択 |
| CA2592177A1 (en) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
| EP1850874B1 (en) | 2005-02-23 | 2013-10-16 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
| SI1904104T1 (sl) | 2005-07-08 | 2013-12-31 | Biogen Idec Ma Inc. | Protitelesa SP35 in njihova uporaba |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| CA2631181A1 (en) | 2005-12-02 | 2007-06-07 | Biogen Idec Ma Inc. | Treatment of conditions involving demyelination |
| US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| MX2009008981A (es) | 2007-03-02 | 2009-09-02 | Genentech Inc | Prediccion de respuesta a un inhibidor her. |
| WO2009048605A1 (en) * | 2007-10-11 | 2009-04-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists |
| CA2702630C (en) * | 2007-11-08 | 2017-11-21 | Biogen Idec Ma Inc. | Use of lingo-4 antagonists in the treatment of conditions involving demyelination |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| DK2982695T3 (da) | 2008-07-09 | 2019-05-13 | Biogen Ma Inc | Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf |
| AU2009308707A1 (en) | 2008-10-31 | 2010-05-06 | Biogen Idec Ma Inc. | LIGHT targeting molecules and uses thereof |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| MX340536B (es) * | 2011-07-06 | 2016-07-13 | Sykehuset Sorlandet Hf | Terapia direccionada al receptor del factor de crecimiento epidermico (egfr). |
| WO2013055874A2 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| JP6180425B2 (ja) | 2011-11-23 | 2017-08-23 | メディミューン，エルエルシー | Ｈｅｒ３に特異的な結合分子及びそれらの使用 |
| WO2013106253A1 (en) | 2012-01-10 | 2013-07-18 | Hzo Inc. | Methods, apparatuses and systems for monitoring for exposure of electronic devices to moisture and reacting to exposure of electronic devices to moisture |
| US9146207B2 (en) | 2012-01-10 | 2015-09-29 | Hzo, Inc. | Methods, apparatuses and systems for sensing exposure of electronic devices to moisture |
| EP2844675B1 (en) | 2012-05-02 | 2019-01-02 | Symphogen A/S | Humanized pan-her antibody compositions |
| CN104470541A (zh) | 2012-05-14 | 2015-03-25 | 比奥根艾迪克Ma公司 | 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂 |
| EP2935333A1 (en) * | 2012-12-21 | 2015-10-28 | Sykehuset Sorlandet HF | Egfr targeted therapy of neurological disorders and pain |
| RU2019115089A (ru) | 2013-04-16 | 2019-06-11 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| CA2918225C (en) | 2013-07-17 | 2023-11-21 | Foundation Medicine, Inc. | Methods of treating urothelial carcinomas |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| JP2017513901A (ja) | 2014-04-25 | 2017-06-01 | ジェネンテック， インコーポレイテッド | トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法 |
| JP2018504400A (ja) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用 |
| US11406715B2 (en) | 2015-05-30 | 2022-08-09 | Genentech, Inc. | Methods of treating HER2-positive metastatic breast cancer |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| AU2017355432A1 (en) | 2016-11-04 | 2019-05-16 | F. Hoffmann-La Roche Ag | Treatment of HER2-positive breast cancer |
| AU2017387909A1 (en) | 2016-12-28 | 2019-06-27 | Genentech, Inc. | Treatment of advanced HER2 expressing cancer |
| SG11201905622VA (en) | 2017-01-17 | 2019-08-27 | Genentech Inc | Subcutaneous her2 antibody formulations |
| US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
| EP3615695A1 (en) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2 mutations in the transmebrane or juxtamembrane domain |
| WO2020115108A1 (en) * | 2018-12-06 | 2020-06-11 | Sørlandet Sykehus Hf | Egfr inhibitors and their use in the treatment of neuroathic pain |
| TWI807338B (zh) * | 2020-06-26 | 2023-07-01 | 美商美國禮來大藥廠 | 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途 |
| AU2020456731A1 (en) | 2020-06-29 | 2023-01-05 | F. Hoffmann-La Roche Ag | Pertuzumab plus trastuzumab fixed dose combination |
| AR125902A1 (es) * | 2021-05-21 | 2023-08-23 | Lilly Co Eli | Compuestos y métodos dirigidos a epirregulina |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| US5824311A (en) * | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| IL101943A0 (en) * | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
| EP1400536A1 (en) * | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| EP0655924A4 (en) | 1992-06-30 | 1996-09-11 | Oncologix Inc | A COMBINATION OF MONOCLONAL ANTIBODIES AGAINST erbB-2 AND METHOD FOR THEIR USE. |
| CA2103323A1 (en) | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
| PT616812E (pt) | 1993-03-24 | 2000-04-28 | Berlex Biosciences | Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro |
| WO1994022478A1 (en) | 1993-03-30 | 1994-10-13 | The Trustees Of The University Of Pennsylvania | PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU) |
| EP0659439B1 (en) | 1993-12-24 | 2001-10-24 | MERCK PATENT GmbH | Immunoconjugates |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| US20020002276A1 (en) * | 1997-02-10 | 2002-01-03 | Genentech, Inc. | Chimeric heteromultimer adhesins |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| IL147017A0 (en) | 1999-06-25 | 2002-08-14 | Genentech Inc | TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES |
| US7041292B1 (en) * | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| JP2006516117A (ja) * | 2002-11-21 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療 |
-
2005
- 2005-04-07 JP JP2007507499A patent/JP4969440B2/ja not_active Expired - Lifetime
- 2005-04-07 WO PCT/US2005/011781 patent/WO2005099756A2/en not_active Ceased
- 2005-04-07 AU AU2005232657A patent/AU2005232657B2/en not_active Expired
- 2005-04-07 EP EP05734984A patent/EP1737489B1/en not_active Expired - Lifetime
- 2005-04-07 CA CA2563341A patent/CA2563341C/en not_active Expired - Lifetime
- 2005-04-07 US US11/102,120 patent/US20060034840A1/en not_active Abandoned
- 2005-04-07 AT AT05734984T patent/ATE540696T1/de active
-
2010
- 2010-11-29 US US12/955,693 patent/US8333964B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007532566A5 (https=) | ||
| Wang et al. | Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents | |
| Gala et al. | Molecular pathways: HER3 targeted therapy | |
| Ford et al. | Targeting epidermal growth factor receptor in head and neck cancer | |
| Yan et al. | HER2 aberrations in cancer: implications for therapy | |
| Cameron et al. | A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses | |
| Hof et al. | Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma | |
| Nielsen et al. | HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors | |
| ES2629405T3 (es) | Combinaciones de un conjugado de fármaco-anticuerpo anti-HER2 y docetaxel | |
| Khalil et al. | Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer | |
| Cassell et al. | Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma | |
| Goetz et al. | In vivo molecular imaging with cetuximab, an anti-EGFR antibody, for prediction of response in xenograft models of human colorectal cancer | |
| JP2010508847A5 (https=) | ||
| JP2010163438A5 (https=) | ||
| JP2009506790A5 (https=) | ||
| JP2009505676A5 (https=) | ||
| Obafemi et al. | A review of global Cancer prevalence and therapy | |
| JP2008508858A5 (https=) | ||
| Pyeon et al. | Abnormally high level of CA-19-9 in a benign ovarian cyst | |
| CN115920078A (zh) | 靶向紧密连接蛋白18.2的抗体药物偶联物 | |
| Kim et al. | Branch duct intraductal papillary mucinous neoplasm of the pancreas: single-center experience with 324 patients who underwent surgical resection | |
| JP2019524706A (ja) | Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用 | |
| WO2018016563A1 (en) | Use of eribulin and histone deacetylase inhibitors in the treatment of cancer | |
| Anitha et al. | HGF/c-MET: a potential target for the treatment of various cancers | |
| JPWO2020174370A5 (https=) |